MedTrace Logo

Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

NCT03037437 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2025-09-04

No results posted yet for this study

Summary

The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with advanced hepatocellular cancer (HCC).

Conditions

  • Hepatocellular Cancer

Interventions

DRUG

Sorafenib (SOR)

Patients will receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).

DRUG

Hydroxychloroquine (HCQ)

400mg by mouth daily

Sponsors & Collaborators

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Sukeshi Patel Arora, MD · Cancer Therapy & Research Center University of Texas Health Science Center San Antonio

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-16
Primary Completion
2025-06-27
Completion
2025-06-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03037437 on ClinicalTrials.gov